Research Papers

25 of 121 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
How Can Implementation Science Improve the Care of Familial Hypercholesterolaemia?
Sarkies M; Jones LK; Pang J; Sullivan D; Watts GF.
Curr Atheroscler Rep (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Health Literacy is Essential to ASCVD Prevention in Youth.
Mann HK; Magnani JW; Johnson AE.
Curr Atheroscler Rep (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Apheresis: What Should a Clinician Know?
Parhofer KG.
Curr Atheroscler Rep (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism.
Giammanco A; Spina R; Cefalù AB; Averna M.
Curr Atheroscler Rep (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues.
Sherratt SCR; Libby P; Budoff MJ; Bhatt DL; Mason RP.
Curr Atheroscler Rep (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
The Dynamic Interplay of Healthy Lifestyle Behaviors for Cardiovascular Health.
Kris-Etherton PM; Sapp PA; Riley TM; Davis KM; Hart T; Lawler O.
Curr Atheroscler Rep (Unknown)
Published: 2022
2/6 Transparent
A Contemporary Review of Epidemiology, Risk Factors, Etiology, and Outcomes of Premature Stroke.
Potter TBH; Tannous J; Vahidy FS.
Curr Atheroscler Rep (Unknown)
Published: 2022
2/6 Transparent
ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis.
Mohamed F; Mansfield BS; Raal FJ.
Curr Atheroscler Rep (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 European Society of Cardiology Congress.
Hermel M; Pelter M; Jordan T; Latif A; Gad MM; Slipczuk L; Kalra D; Virani SS.
Curr Atheroscler Rep (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond.
Seidah NG; Garçon D.
Curr Atheroscler Rep (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Bempedoic Acid: for Whom and When.
Ruscica M; Sirtori CR; Carugo S; Banach M; Corsini A.
Curr Atheroscler Rep (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
COVID-19 and Cardiometabolic Health: Lessons Gleaned from the Pandemic and Insights for the Next Wave.
Kolkailah AA; Riggs K; Navar AM; Khera A.
Curr Atheroscler Rep (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women an…
Gauci S; Cartledge S; Redfern J; Gallagher R; Huxley R; Lee CMY; Vassallo A; O'Neil A.
Curr Atheroscler Rep (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American College of Cardiology Scientific…
Hermel M; Tsai S; Dlouhy L; B K A; Rana JS; Dani SS; Virani SS.
Curr Atheroscler Rep (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Cardio-Obstetrics: the Next Frontier in Cardiovascular Disease Prevention.
Thakkar A; Hailu T; Blumenthal RS; Martin SS; Harrington CM; Yeh DD; French KA; Sharma G.
Curr Atheroscler Rep (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.
Kalayci A; Gibson CM; Ridker PM; Wright SD; Kingwell BA; Korjian S; Chi G; Lee JJ; Tricoci P; Kazmi SH; Fitzgerald C; Shaunik A; Berman G; Duffy D; Libby P.
Curr Atheroscler Rep (Unknown)
Published: 2022
2/6 Transparent
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease.
Martin A; Lang S; Goeser T; Demir M; Steffen HM; Kasper P.
Curr Atheroscler Rep (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Free Cholesterol Bioavailability and Atherosclerosis.
Abe RJ; Abe JI; Nguyen MTH; Olmsted-Davis EA; Mamun A; Banerjee P; Cooke JP; Fang L; Pownall H; Le NT.
Curr Atheroscler Rep (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Treating Cardiovascular Disease with Liver Genome Engineering.
Hurley A; Lagor WR.
Curr Atheroscler Rep (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease.
Packard CJ.
Curr Atheroscler Rep (Unknown)
Published: 2022
2/6 Transparent
SR-B1's Next Top Model: Structural Perspectives on the Functions of the HDL Receptor.
Powers HR; Sahoo D.
Curr Atheroscler Rep (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins.
Visser J; van Zwol W; Kuivenhoven JA.
Curr Atheroscler Rep (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions.
Lee MT; George J; Shahab H; Hermel M; Rana JS; Virani SS.
Curr Atheroscler Rep (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors.
Pirillo A; Catapano AL; Norata GD.
Curr Atheroscler Rep (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?
Parhofer KG.
Curr Atheroscler Rep (Unknown)
Published: 2021
2/6 Transparent
Funding Declared